Safety of tiotropium
نویسندگان
چکیده
منابع مشابه
Tiotropium safety in ‘real‐world’ populations
We read with interest the publication of Schmiedl et al. describing the characteristics of patients treated with tiotropium HandiHaler or Respimat in the Tiotropium Safety and Performance in Respimat (TIOSPIR) study compared with their ‘real-world’ database [1]. The authors noted that patients starting either treatment had similar characteristics but suggest that we may have included a selected...
متن کاملTiotropium HandiHaler® in the treatment of COPD: A safety review
BACKGROUND Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since 2002. We sought to update an evaluation of the safety of tiotropium in the HandiHaler formulation as significant clinical trial data have become available over time. METHODS Pooled analysis of adverse event reporting from phase...
متن کاملEfficacy and Safety of Tiotropium in Children and Adolescents
Asthma is one of the most common chronic diseases in children, with a high proportion of patients demonstrating poor control despite the availability of disease management guidelines. Global Initiative for Asthma guidelines include tiotropium as an add-on therapy option at Steps 4 and 5 in patients aged ≥ 12 years with a history of exacerbations, and tiotropium delivered via the Respimat® Soft ...
متن کاملSafety, tolerability and risk benefit analysis of tiotropium in COPD
COPD is a chronic disease and, like many other chronic diseases, there is no treatment to reverse the severity of the disease except for lung transplant. To date, no inhaled medications have been shown to improve survival. Tiotropium bromide is a long-acting inhaled anticholinergic drug for the treatment of COPD that can improve lung function, reduce symptoms and exacerbations, and improve qual...
متن کاملTiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis
INTRODUCTION Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (COPD) and delivered via HandiHaler(®) (18 μg once daily) or Respimat(®) Soft Mist™ inhaler (5 μg once daily). The recent TIOtropium Safety and Performance In Respimat(®) (TIOSPIR™) study demonstrated that both exhibit similar safety profiles. This analysis provides an updated comprehensive safety e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2011
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.d2970